Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1358-1374

  Gianfrancesco, Frank D ^a   Sajatovic, Martha ^b   Rajagopalan, Krithika ^c   Wang, Ruey Hua ^a  

^a HECON Associates Inc   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

adherence; antipsychotic; bipolar disorder; depressive; manic mixed

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; LITHIUM; LOXAPINE; MESORIDAZINE; MOLINDONE; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DATA BASE; DEPRESSION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL HEALTH CARE; MULTIPLE REGRESSION; OUTPATIENT; PHARMACY; RISK; TREATMENT DURATION;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MENTAL HEALTH SERVICES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE;

EID: 48549083256     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80062-8     Document Type: Article

References (42)

1. Sajatovic M., Valenstein M., Blow F.C., et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 8 (2006) 232-241
2. Svarstad B.L., Shireman T.I., and Sweeney J.K. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52 (2001) 805-811
3. Perlick D.A., Rosenheck R.A., Kaczynski R., and Kozma L. Medication non-adherence in bipolar disorder: A patientcentered review of research findings. Clin Approaches Bipolar Disord 3 (2004) 56-64
4. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 (2004) 886-891
5. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
6. Eaddy M., Grogg A., and Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 27 (2005) 263-272
7. Knapp M., King D., Pugner K., and Lapuerta P. Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. Br J Psychiatry 184 (2004) 509-516
8. Rittmannsberger H., Pachinger T., Keppelmüller P., and Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 55 (2004) 174-179
9. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161 (2004) 692-699
10. Ascher-Svanum H., Faries D.E., Zhu B., et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67 (2006) 453-460
11. Lew K.H., Chang E.Y., Rajagopalan K., and Knoth R.L. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 19 (2006) 41-46
12. Bowden C.L., Collins M.A., McElroy S.L., et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology 30 (2005) 1932-1939
13. Bowden C.L., and Singh V. Valproate in bipolar disorder: 2000 Onwards. Acta Psychiatr Scand Suppl 426 (2005) 13-20
14. Bowden C.L. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 65 Suppl 15 (2004) 21-24
15. Fu A.Z., Krishnan A.N., Harris S.D., and Thompson T.R. The economic burden of bipolar-related phases of depression versus mania. Drug Benefits Trends 16 (2004) 569-575
16. Gianfrancesco F.D., Rajagopalan K., Sajatovic M., and Wang R.H. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 67 (2006) 222-232
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (2000), APA, Washington, DC Text Revision: DSM-IV-TR
18. Valenstein M., Copeland L.A., Blow F.C., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40 (2002) 630-639
19. Al-Zakwani I.S., Barron J.J., Bullano M.F., et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 19 (2003) 619-626
20. Gianfrancesco F., Wang R.H., and Pesa J. Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value Health 8 (2005) 471-478
21. Gianfrancesco F., Pesa J., and Wang R.H. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Manag Care Pharm 11 (2005) 220-230
22. Hamilton R.A., and Briceland L.L. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 49 (1992) 1691-1696
23. Goodwin F.K. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 64 Suppl 5 (2003) 18-24
24. Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 63 Suppl 10 (2002) 23-28
25. Dunner D.L. Atypical antipsychotics: Efficacy across bipolar disorder subpopulations. J Clin Psychiatry 66 Suppl 3 (2005) 20-27
26. Owen R.R., Fischer E.P., Booth B.M., and Cuffel B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 47 (1996) 853-858
27. Olfson M., Mechanic D., Hansell S., et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 51 (2000) 216-222
28. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63 (2002) 892-909
29. Nosé M., Barbui C., and Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med 33 (2003) 1149-1160
30. Keck Jr. P.E., McElroy S.L., Strakowski S.M., et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 57 (1996) 292-297
31. Russo P., Smith M.W., Dirani R., et al. Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disord 4 (2002) 366-377
32. Gibson T.B., Ozminkowski R.J., and Goetzel R.Z. The effects of prescription drug cost sharing: A review of the evidence. Am J Manag Care 11 (2005) 730-740
33. Frank R.G., and McGuire T.G. A review of studies of the impact of insurance on the demand and utilization of specialty mental health services. Health Serv Res 21 (1986) 241-265
34. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 Suppl 4 (2002) 1-50
35. Keck PE Jr, Perlis RH, Otto MW, et al, The Expert Consensus Guideline Series: Treatment of bipolar disor der 2004. Postgrad Med Special Rep. December 2004.
36. (2008). http://www.psychguides.com/Bipolar%20disorder%202004%20front%20matter.pdf July 1, Accessed
37. Goodwin G.M., and Young A.H. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: A summary. J Psychopharmacol 17 Suppl 4 (2003) 3-6
38. Yatham L.N., Kennedy S.H., O'Donovan C., et al. for the Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 7 Suppl 3 (2005) 5-69
39. Colom F., and Vieta E. Treatment adherence in bipolar patients. Clin Approaches Bipolar Disord 1 (2002) 49-56
40. Suppes T., Baldessarini R.J., Faedda G.L., and Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 48 (1991) 1082-1088
41. Scott J. Predicting medication nonadherence in severe affective disor ders. Acta Neuropsychiatry 12 (2000) 128-130
42. Müller-Oerlinghausen B., Müser-Causemann B., and Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 25 (1992) 261-269